Pharmacokinetics of sulfaclomide and sulfamerazine in patients with impaired renal function after first and after repeated application.
At the beginning of the therapy with sulfaclomide resp. sulfamerazine elimination half-life of sulfaclomide was prolonged significantly in patients with impaired renal function (creatinine in serum greater than 2 mg/100 ml) on 119.6+/-6.9 h in comparison to control group (83.6+/-14.5 h). Half-life of sulfamerazine (23.6+/-4.1 h) did not differ from that of the control group (20.3+/-2.8 h). Renal excretion of both sulfonamides was sharply diminished. After treatment for 11 days with sulfaclomide resp. sulfamerazine in patients with impaired renal function, half-lives were prolonged to 117.3+/-6.1% resp. 119.3+/-3.9% of the initial value. In patients with impaired renal function elimination half-life of PAH as a measure of tubular function is three times that of control group. It is not statistically significantly influenced by repeated administration of the sulfonamides. In the control group there is a shortening of the PAH-half-life under the same conditions.
D000293:Adolescent; D000328:Adult; D005260:Female; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000008:administration & dosage / Q000378:metabolism; D013416:Sulfamerazine / Q000008:administration & dosage / Q000378:metabolism*; D013424:Sulfanilamides / Q000008:administration & dosage / Q000378:metabolism*; D013997:Time Factors; D010130:p-Aminohippuric Acid / Q000378:metabolism; D000096926:Benzenesulfonamides
D011743:Pyrimidines; D013416:Sulfamerazine; D013424:Sulfanilamides; D010130:p-Aminohippuric Acid; C005740:sulfaclomide; D000096926:Benzenesulfonamides